Navigation Links
Zimmer Reports Fourth Quarter and 2007 Financial Results
Date:1/29/2008

/p>

Asia Pacific 197 18 13

Total 1,637 12 9

Hips

Americas 630 9 8

Europe 468 12 4

Asia Pacific 201 5 3

Total 1,299 9 6

Extremities 104 34 31

Dental 221 23 20

Trauma 206 6 3

Spine 197 11 10

OSP and other 234 8 6

Net earnings for the fourth quarter were $264 million on a reported basis and $276 million on an adjusted basis, an increase of 13% adjusted over the prior year period. Net earnings for the full year 2007 were $773 million on a reported basis and $962 million on an adjusted basis, an increase of 14% adjusted over the prior year.

Guidance

Full year 2008 net sales are expected to be approximately 10 to 11% over 2007, including an approximate favorable foreign currency impact of 2%. Adjusted diluted earnings per share for the full year 2008 are expected to be $4.20 to $4.25, reflecting an increase of approximately 4 to 5% over prior year. The guidance reflects the expected costs for a number of ongoing infrastructure and operating initiatives, including upgrades to the Company's U.S. sales and distribution capabilities, such as inventory tracking and instrumentation; enhancements to information technology and quality systems; increased investments in sales force and other marketing programs in the Spine, Dental and Trauma business units; and start-up costs for an expansion of worldwide manufactu
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
2. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
3. Zimmer Holdings to Present at JPMorgan Healthcare Conference
4. Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee
5. Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman
6. Zimmer Holdings to Present at Upcoming Investor Conferences
7. Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid
8. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
9. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
10. Amylin Pharmaceuticals Reports 2007 Financial Results
11. Cystic Fibrosis Foundation reports upward trend for key health outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...tients treated with radiation prior to surgery for...ncer recurrence and better overall survival rates,...eport examined a treatment called neoadjuvant ther...t the spread of cancer, before surgery to remove t...rapy and/or radiation. , Neoadjuvant therapy sh...
(Date:12/2/2008)...2008 - Elsevier announced today the publication of...the theme of "Second trimester abortion: women,s h...on raises complex issues regarding methods, values...ery and the sometimes complicated reality of women...ve Health Matters grew out of a conference on sec...
(Date:12/2/2008)... probably higher with aprotinin, a drug commonly u...cardiac surgery, compared with lysine analogues, a...pdf/cmaj.081109 to be published in the January 20...anada expert advisory panel will meet to decide on...in advance of the meeting. , The study, a syste...
(Date:12/2/2008)... published in the December 1, 2008, issue of Clin...ssociation for Cancer Research, show lapatinib ben...e women with HER2-negative breast cancer or those ...it. In addition, a misclassification of metastatic...revents some people from receiving optimal therapy...
Breaking Medicine News(10 mins):Health News:Elsevier announces the 2008 supplement of Reproductive Health Matters 2Health News:HER2 levels may aid in treatment selection for metastatic breast cancer 2
...ing weight by dietary changes and increased physic...condition where blood glucose// levels are higher ...ese are the results of a new study that was publis...Care, of women who participated in the Diabetes Pr...
...e being hit the most by obesity-related disorders....ne by doctors that fails to// detect these problem...ight divided by height- is used in the standard me...ing to the experts, East and South Asians were aff...
...n Canada ahead of HIV/AIDS, diabetes and car accid...inal communities. With World// Suicide Prevention ... from the Canadian Institutes of Health Research (...lenges posed by suicide, its causes and possible p...
...er a period of 30 years and has infected many peop...Recently, 3 people in Delhi// have tested positive...rs who transmit chikungunya fever to human. The N...able Diseases (NICD) tested 6 blood samples of whi...
Other Medicine News:Health News:Bladder Control following Weight loss in women with Prediabetes 2Health News:Bladder Control following Weight loss in women with Prediabetes 3Health News:Getting Serious About Suicide Prevention 2
(Date:12/2/2008)...LA, Calif., Dec. 2 TorreyPines The...positive results from a 26 patient Phase II trial ...r xerostomia, or dry mouth, in patients with Sjogr... a statistically significant increase in salivary ...oses: 10 mg, 15 mg, and 20 mg. These doses were sa...
(Date:12/2/2008)..., Ill., Dec. 2 Horizon Therapeutic...ny, today announced that two pivotal,Phase 3 tria...didate, HZT-501,met all primary endpoints. HZT-5...roduct containing ibuprofen and famotidine, demons...he incidence of non-steroidal,anti-inflammatory d...
(Date:12/2/2008)...DA, Md., Dec. 2 Micromet...any developing novel, proprietary antibodies for t...e diseases, today announced that it has entered in...ancing Facility (CEFF) with Kingsbridge Capital Li...s of the agreement, Kingsbridge has committed to p...
(Date:12/1/2008)...O, Dec. 2 New research ...t-slice computed tomography (CT) scanner in an eme...of stroke victims who receive a potentially life-s...t North Shore Medical Center (NSMC)-Salem Hospital...nnual meeting of the Radiological Society of North...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 1OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 2OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 3New technique produces genetically identical stem cells 6347 1New technique produces genetically identical stem cells 6347 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 1Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 3Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 4Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 5Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 1Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 2Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 3
...ta to be Presented April 15th at EASL Conference i...pril 11, 2007,/PRNewswire-FirstCall/ - MIGENIX Inc...ious diseases, has received new top-line results,c...s (November 6,2006) indicating evidence of clinic...study using the oral alpha-glucosidase,inhibitor, ...
...MBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gl...d biopharmaceutical,company, announced today that ...omidepsin will be presented at the 2007,Annual Mee...h,taking place in Los Angeles, CA April 14-18, 200...preclinical research,performed by multiple academi...
Other Medicine Technology:New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 2Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: